<DOC>
	<DOC>NCT00150761</DOC>
	<brief_summary>Phase IV, human pharmacology, exploratory, randomized, 3-way (3 treatment periods) cross-over, double blind, double dummy, placebo controlled study to compare levocetirizine and cetirizine by means of IR thermography.</brief_summary>
	<brief_title>Facial Thermography Study of Levocetirizine Versus Cetirizine</brief_title>
	<detailed_description />
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Healthy male Caucasian subject aged between 18 and 55 years (both inclusive). Subject must have a positive prick test to histamine (wheal diameter ≥ 6 mm with histamine dihydrochloride (100 mg/mL) and ≤ 3 mm with diluent control). History of allergic disease, documented or suspected, including but not limited to: asthma, whether or not considered as allergic; nocturnal cough episode suspected to be of asthmaequivalent nature (three or more consecutive nights resulting in sleep disturbances) ; allergic rhinitis, conjunctivitis or sinusitis; nasal polyposis; dermatitis of the face or neck; drug or food allergy. Any clinically significant vascular disease such as hyper or hypotension, venous disorder, vasculitis etc. History of hot flushes and any other vasomotor disorders. ENT infection or Upper Respiratory Tract Infection not completely cured at least one week before inclusion. Any known history of laryngeal edema. Nasal structural abnormalities (e.g. deviation of the nasal septum…). Recent immunotherapy Skin irritants or UV exposure 48 hours before each visit.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Nasal histamine provocation, facial thermography, levocetirizine, cetirizine,</keyword>
	<keyword>Xyzal, Zyrtec</keyword>
</DOC>